Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E31.40 EPS (ttm)1.61 Insider Own1.80% Shs Outstand1.66B Perf Week2.99%
Market Cap83.82B Forward P/E28.74 EPS next Y1.76 Insider Trans120.28% Shs Float1.65B Perf Month-1.15%
Income2.69B PEG3.21 EPS next Q0.42 Inst Own71.10% Short Float2.02% Perf Quarter3.67%
Sales16.21B P/S5.17 EPS this Y32.80% Inst Trans-0.11% Short Ratio5.79 Perf Half Y0.60%
Book/sh9.25 P/B5.47 EPS next Y-1.18% ROA7.60% Target Price53.79 Perf Year4.59%
Cash/sh4.33 P/C11.68 EPS next 5Y9.77% ROE17.70% 52W Range45.63 - 56.27 Perf YTD-2.81%
Dividend1.44 P/FCF68.32 EPS past 5Y-3.60% ROI10.70% 52W High-10.15% Beta0.40
Dividend %2.85% Quick Ratio1.60 Sales past 5Y-1.50% Gross Margin73.30% 52W Low10.80% ATR1.03
Employees28000 Current Ratio1.80 Sales Q/Q-3.90% Oper. Margin22.30% RSI (14)53.61 Volatility2.34% 1.97%
OptionableYes Debt/Eq0.50 EPS Q/Q-37.50% Profit Margin16.60% Rel Volume1.01 Prev Close50.42
ShortableYes LT Debt/Eq0.48 EarningsOct 24 BMO Payout87.10% Avg Volume5.78M Price50.56
Recom2.30 SMA200.41% SMA500.84% SMA2001.03% Volume5,827,244 Change0.28%
25-Jul-14Reiterated MKM Partners Sell $29 → $34
15-Jan-14Reiterated Argus Buy $58 → $62
10-Jan-14Upgrade Barclays Equal Weight → Overweight $52 → $65
20-Dec-13Reiterated UBS Neutral $48 → $54
29-Jul-13Reiterated Argus Buy $54
17-Jul-13Reiterated Barclays Equal Weight $42 → $45
04-Jun-13Reiterated Argus Buy $46 → $54
26-Apr-13Reiterated MKM Partners Sell $26 → $29
15-Apr-13Reiterated Barclays Equal Weight $33 → $42
25-Jan-13Reiterated UBS Neutral $34 → $36
09-Jan-12Reiterated Barclays Capital Overweight $34 → $36
19-Oct-11Initiated MKM Partners Sell $26
27-Jun-11Reiterated UBS Neutral $28 → $30
31-Mar-11Downgrade Jefferies Buy → Hold $28.50
28-Mar-11Reiterated Barclays Capital Overweight $28 → $30
22-Sep-10Reiterated Deutsche Bank Buy $28 → $31.50
01-Sep-10Reiterated UBS Neutral $26 → $27
31-Aug-10Upgrade Jefferies Hold → Buy $28.80 → $30
12-Mar-10Initiated Jefferies & Co Hold $27
16-Dec-09Initiated UBS Neutral
20-Oct-14 12:34PM  AstraZeneca, Bristol-Myers Wont Face Kickback Lawsuit at Bloomberg
17-Oct-14 08:16PM  Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan at TheStreet
06:14PM  Cramer: Tune in for the most vital earnings week at CNBC
04:50PM  Next week's earnings: Tech takes center stage CNBC
03:12PM  5 Dividend Stocks Ready to Give Investors a Raise at TheStreet
02:41AM  Roche, Merck extend immunotherapy fight to breast cancer Reuters
16-Oct-14 08:10PM  AbbVie Kills Shire Merger, But Door Opens for Bristol-Myers Squibb? at TheStreet
10:13AM  How Will Bristol-Myers Squibb (BMY) Stock React Today to This Upgrade? at TheStreet
15-Oct-14 06:00AM  Biotech's Builder: How The Pharma's Landlord Could Benefit From The Drug Boom at Forbes
14-Oct-14 04:20PM  Bristol-Myers Collaborates for Opdivo-Imbruvica Combo Zacks
13-Oct-14 09:00AM  Bristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights Business Wire
08:07AM  5 Companies That Could Develop An Enterovirus Treatment Benzinga
08:00AM  Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma Business Wire
10-Oct-14 04:32PM  U.S. FDA approves Gilead's $94,500 hepatitis C drug Reuters
09-Oct-14 06:25PM  Cramer: Activists are picking on the wrong chiefs at CNBC
02:00PM  Scientists find lung cancer can lie hidden for 20 years Reuters
08-Oct-14 05:10PM  Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo Zacks
08:00AM  Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. Business Wire
04:32AM  Cramer: Trust the Bristol-Myers Theorem TheStreet
02:31AM  [$$] Bristol-Myers Drops Hepatitis C Dual Regimen in U.S. at The Wall Street Journal
07-Oct-14 04:10PM  Why Bristol-Myers Squibb (BMY) Stock Declined Today at TheStreet
03:50PM  Novartis Collaborates with Bristol-Myers Squibb Zacks
11:13AM  Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo at Investor's Business Daily
11:04AM  UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Reuters
10:44AM  [$$] Bristol-Myers Drops Hepatitis C Dual Regimen in U.S. at The Wall Street Journal
09:03AM  Bristol-Myers Gives Up on Hepatitis C Combination in U.S. at Bloomberg
08:51AM  Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Reuters
08:30AM  Bristol-Myers Squibb Statement about Asunaprevir in the U.S. Business Wire
03:27AM  Pension Dropouts Cause Pinch at The Wall Street Journal
06-Oct-14 10:38AM  2 Mutual Funds Holding Hospital Stocks Benzinga
09:24AM  [$$] Bristol-Myers, Novartis to Combine Cancer Treatments in Trials at The Wall Street Journal
08:00AM  Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer (NSCLC) Business Wire
08:00AM  Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies Business Wire
07:30AM  AstraZeneca heart drug gets preferred status in U.S. Reuters
01:17AM  Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC Thomson Reuters ONE
05-Oct-14 10:31PM  '60 Minutes' Just Attacked High Drug Prices. Here's What You Should Know. at Forbes
03-Oct-14 08:00AM  Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014 Showcasing Continued Innovation in Virology Business Wire
02-Oct-14 08:55AM  Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst at 24/7 Wall St.
05:03AM  The Zacks Analyst Blog Highlights: ELEMENTS Spectrum Large Cap U.S. Sector Momentum Index ETN, db X-trackers Harvest CSI 500 China-A Shares Small Cap, MSCI Qatar Capped ETF, AbbVie and Bristol-Myers Squibb Zacks
12:01AM  Hedge Funds Listen In on Patient Chats for Pharma Bets Bloomberg
01-Oct-14 04:00PM  Bristol-Myers' Opdivo under Review in EU for Lung Cancer Zacks
03:30PM  AbbVie Announces Positive Results on Oncology Candidate Zacks
11:57AM  [$$] Immuno-Oncology Agents Get Another Boost at Barrons.com
10:00AM  Bristol-Myers Squibb to Announce Results for Third Quarter on October 24 Business Wire
08:50AM  Abbott Labs Completes CFR Pharmaceuticals Acquisition Zacks
08:28AM  INNATE PHARMA : INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB IN COMBINATION WITH ELOTUZUMAB Thomson Reuters ONE
08:00AM  Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance GlobeNewswire
30-Sep-14 05:45PM  [$$] Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations at The Wall Street Journal
05:00PM  Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential Business Wire
11:10AM  Valeant's Bausch + Lomb Announces Results on Lotemax Zacks
29-Sep-14 05:50PM  Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment Zacks
03:35PM  Novartis Gives Updates on Signifor LAR and Secukinumab Zacks
01:28PM  How to play volatility CNBC
01:28PM  [video] How to play volatility at CNBC
11:14AM  Cancer drug stocks on the move amid striking data at CNBC
08:21AM  European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer Business Wire
08:11AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers, Johnson & Johnson, AbbVie and Medivation Zacks
03:00AM  Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor Business Wire
03:00AM  Bristol immune drug shows strong effect in melanoma study Reuters
26-Sep-14 05:26PM  Fast Money Final Trade: XOM, HYG, YHOO & BMY CNBC
05:26PM  [video] Fast Money Final Trade: XOM, HYG, YHOO & BMY at CNBC
05:08PM  Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Reuters
04:18PM  Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union Business Wire
03:30PM  Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance Zacks
01:04PM  BMY, MRK And PFE, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
25-Sep-14 06:57PM  Cramer's Remix: Selloff strategies to survive drop at CNBC
06:28PM  Cramer's Bristol-Myers theorem: What is it? at CNBC
01:33AM  INNATE PHARMA: Third DSMB for EffiKIR trial recommends continuation as planned Thomson Reuters ONE
24-Sep-14 05:29PM  Gilead's New HIV Drug Key To Long-Term Strategy at Investor's Business Daily
22-Sep-14 08:00AM  Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers Business Wire
19-Sep-14 05:04PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia EDGAR Online
04:40PM  Bristol-Myers' (BMY) Yervoy Label Expanded in Canada Zacks
18-Sep-14 03:55PM  Merck Enters into Licensing Agreement with Sun Pharma Zacks
17-Sep-14 05:13PM  [$$] Bristol-Myers CEO Sells $2.5 Million in Stock at Barrons.com
16-Sep-14 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
08:10AM  What Ralph Nader Gets Wrong About Big Pharma at Forbes
05:59AM  Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer CNW Group
15-Sep-14 11:35AM  Video: Gilead OKs Generic Sovaldi To Expand Access at Investor's Business Daily
12-Sep-14 08:43AM  Up and Down the Ladder: The Latest Comings and Goings at FDA, Cardinal Health and at The Wall Street Journal
11-Sep-14 11:30AM  Insider Trading Alert - BMY, AMBA And MTD Traded By Insiders at TheStreet
10:00AM  Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference Business Wire
09-Sep-14 06:00AM  Bristol-Myers Needs a Healthy Growth Shot to Justify Its Valuation at TheStreet
08-Sep-14 06:24PM  Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent at The Wall Street Journal
03:30PM  Bristol-Myers Sues Merck of Patent Infringement on Keytruda Zacks
11:11AM  [$$] A New Era in Immuno-Oncology at Barrons.com
10:18AM  Bristol-Myers Sues Merck Over a Patent on its new Cancer Drug at The Wall Street Journal
08:48AM  J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig at TheStreet
06:14AM  Bristol-Myers bulls back for more optionMONSTER
05-Sep-14 09:25PM  Bristol-Myers sues Merck over U.S. immunotherapy patent Reuters
04:04PM  Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug Benzinga
02:12PM  Bristol-Myers Sues Merck Over Cancer Immunotherapy Patent at Bloomberg
10:20AM  Merck's Anti-PD-1 Drug Keytruda First to be Launched in US Zacks
06:14AM  Bristol-Myers bulls looking for rally optionMONSTER
04-Sep-14 04:33PM  Merck PD-1 Inhibitor Approved For Skin Cancer at Investor's Business Daily
03:44PM  U.S. approves Merck immune-stimulating drug for melanoma Reuters
12:11AM  [$$] Powerful New Cancer Drugs Offer Hopeat Steep Cost at The Wall Street Journal
03-Sep-14 08:01PM  [$$] New Cancer Drugs Offer Hope---at Steep Cost at The Wall Street Journal
04:22PM  Drug M&A Boom Driven By Long-Term Trends: PwC at Investor's Business Daily
10:45AM  Credit Suisses 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014 24/7 Wall St.
10:02AM  Bristol-Myers Returns Clazakizumab Rights, Alder Sinks Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances and collaborations with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM
Caforio GiovanniEVP & Chief Commercial OfficerJan 03Option Exercise0.007,500054,817Jan 06 05:40 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660201,827Nov 04 04:20 PM